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ORIGINAL RESEARCH

Monthly Trends of Substance Use Among Mainers Receiving
Buprenorphine Treatment During the COVID-19 Pandemic
Sarosh Khan, BA1
1

University of New England College of Osteopathic Medicine, Portland, ME

Introduction:

Drug-related deaths in Maine increased by 23% in the first quarter of 2020 compared to the last quarter
of 2019. Most of these deaths were accidental overdoses involving at least one opioid, and 65% of these
deaths were caused by fentanyl, according to the Maine Center for Disease Control and Prevention.

Methods:

This research explored substance use in Maine during 2020. Among the sample of individuals, 46%
were homeless and receiving recovery services at a buprenorphine-assisted treatment program at a
federally qualified health center in Maine. Charts of 35 patients were reviewed for emergency room
visits and urine drug screens.

Results:

In the sample, 20% of individuals screened positive for fentanyl, 22% screened positive for
methamphetamines, and 20% screened positive for cocaine. In the first month after lockdown, the
presence of fentanyl and methamphetamines in urine drug screens doubled compared to before the
lockdown. In the months after lockdown, the amounts of fentanyl and methamphetamines in drug
screens and the number of emergency room visits increased.

Discussion:

Examples of Maine’s harm-reduction strategies are discussed. These results highlight the urgency to
implement more drastic measures statewide, especially among individuals who are homeless and have
an opioid and/or a stimulant use disorder.

Conclusion:

Greater recovery services are required for individuals who are homeless and have a substance use
disorder in the aftermath of the pandemic.
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D

rug-related deaths in Maine increased by
23% in the first quarter of 2020 compared
to the last quarter of 2019. Most of these
deaths were accidental overdoses involving at least
one opioid.1 This alarming rise in overdose-related
fatalities, also seen nationwide, is due, in part, to
the increased use of non-pharmaceutical fentanyl
and its analogs, as well as the additional burden
of psychosocial stress related to COVID-19.1-3
According to the Maine Center for Disease Control
and Prevention, almost 83% of drug-related deaths
in 2020 were caused by an overdose of an opioid.1
Of these deaths, 65% were caused by fentanyl,
and the remaining were caused by pharmaceutical
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opioids, cocaine, methamphetamines, and heroin.
The combinations of fentanyl with cocaine or
with methamphetamines were particularly fatal.1,2
Statewide, the number of opioid overdoses that
presented to emergency rooms increased by 17%
in 2020 compared to 2019.4,5
Nationally, a record number of over 81,000
individuals died of a drug overdose between June
2019 and May 2020.3 In an analysis of 190 million
emergency room visits from 48 states, emergency
room visits for mental health conditions, suicidal
ideation, drug and opioid overdoses, intimate
partner violence, and child abuse and neglect
were higher between March and October 2020
compared to the same period in 2019. Despite an
overall decrease in emergency room visits due to
lockdown restrictions, drug and opioid overdoses
1
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increased by 16% (drug) and 32% (opioid) in 2020
compared to 2019.6
Psychosocial stressors related to COVID-19
disproportionately affect people with substance
use disorders.7-9 The distress associated with the
pandemic may increase the risk of recurrence
of use, overuse, and drug-related fatalities.8,10,11
Individuals with a substance use disorder are also
more likely to face food and housing insecurity,
reduced access to health care, an increased risk
of contracting respiratory infections, and worse
outcomes from COVID-19.7,12-14
Due to the nationally rising prevalence of opioid use
disorder, medication-assisted treatment programs
in the primary care setting encourage treatment
adherence and access to care.15 The therapeutic
model for such programs with buprenorphine
maintenance therapy uses buprenorphine’s property
as a partial opioid agonist with high affinity at the mu
opioid receptor. Buprenorphine also has a safety
profile due to its ceiling effect, limiting its misuse and
overdose potential. Medication-assisted treatment
with buprenorphine and methadone are highly
efficacious in promoting patient survival, retention
in treatment, and improved psychosocial outcomes
among people with an opioid use disorder.16-18
This retrospective chart review was conducted
during the pandemic at a medication-assisted
treatment program with a low barrier and a focus
on harm reduction. This manuscript presents a
preliminary exploration of monthly substance use
and emergency room visits among a cohort of
individuals who were in recovery for an opioid use
disorder.

Figure 1 shows a brief timeline of some of the social
distancing and public health measures enacted by
the state of Maine during the COVID-19 pandemic
in 2020.19

METHODS
Sample and procedure
I reviewed charts from patients receiving
buprenorphine maintenance treatment for opioid
use disorder at Penobscot Community Health
Center, a federally qualified health center in
Maine’s Penobscot County. This opioid treatment
program is office-based and uses a collaborative
care model that includes counseling, individual
and group therapy, medication management, and
psychiatric evaluations in a primary care setting.
A retrospective chart review was conducted on
patients enrolled in a buprenorphine-naloxone
or extended-release buprenorphine treatment
program. Institutional review board approval and
Health Insurance Portability and Accountability Act
exemption was obtained.
Charts were included if patients (1) were adults at
least 18 years old, (2) were receiving sublingual
buprenorphine-naloxone (Suboxone) weekly or
every two weeks in January 2020 to December
2020, and (3) had a urine drug screen available for
each month of 2020.
I reviewed 50 charts of all patients enrolled in the
medication-assisted treatment program. Among
these charts, 15 were excluded because they did
not meet the inclusion criteria, yielding a study
sample of 35 charts.

Figure 1. Timeline of Maine’s response to the COVID-19 Pandemic
https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss1/2
DOI: 10.46804/2641-2225.1099

2

Khan: Substance Use among Mainers Receiving Buprenorphine Treatment

Among the study sample, almost half of individuals
(N = 16; 46%) were homeless and living in a
homeless shelter or transitional housing. Patients
were seen on a weekly, every two weeks, or
monthly basis based on clinical evaluation. Doses
of Suboxone ranged from 8 to 20 mg.
During every visit, the Patient Health Questionnaire-9
(PHQ-9), a self-reported 9-item scale used to screen
for depression,20 was administered. For each month
of 2020, I analyzed a urine drug screen, which
included a qualitative and quantitative summary
of buprenorphine, naloxone, heroin, oxycodone,
methadone, cocaine, benzodiazepines, marijuana,
methamphetamines, tobacco, alcohol, and fentanyl
breakdown products. Charts were also reviewed for
the number of emergency room visits per month.
Demographic information, housing status, and
depression severity scores were obtained.
Data was analyzed using Microsoft Excel,
Version 16.52. The percentage of individuals who
screened positive for nicotine, marijuana, cocaine,
methamphetamines, and fentanyl, and the amounts
of each substance, were analyzed by month.

RESULTS
Characteristics of the sample: demographics,
substance use, and housing status
Among the sample (N = 35), 60% of individuals
identified as male, and 40% identified as female. All
individuals identified as White, Non-Hispanic. The
average age of individuals was 44 years. Among
the cohort, 46% of individuals were homeless,
living either in transitional housing or in a homeless
shelter. Based on urine drug screens averaged
across the 12 months of 2020, 92% of individuals
screened positive for nicotine breakdown products,
60% screened positive for marijuana, 22% screened
positive for methamphetamines, 20% screened
positive for fentanyl, and 20% screened positive for
cocaine. Also, 77% of individuals had an average
PHQ-9 score that corresponded with moderatesevere depression. (Table 1)
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Table 1. Demographic Characteristics, Housing
Status, Drug Screen Results, and Depression
Among the Sample (N = 35)

Characteristic
Sex
Female
Male
Non-binary
Age, y
18-25
25-44
45-64
Race/Ethnicity
White, Non-Hispanic
Depression severity*
None (1-4)
Mild (5-9)
Moderate (10-14)
Moderately severe (15-19)
Severe (20-27)
Homeless
Yes
No
Overall results of urine drug
screen†
Nicotine
Marijuana
Fentanyl
Methamphetamines
Cocaine

No. (%)
14 (40)
21 (60)
0 (0)
0 (0)
19 (54)
16 (46)
35 (100)
4 (11)
4 (11)
8 (2)
17 (48)
2 (5)
16 (46)
19 (54)

32 (92)
21 (60)
7 (20)
8 (22)
7 (20)

*Assessed with the Patient Health Questionaire-9.
†Averaged over 12 months.

Positive trends in the number of emergency room
visits, as well as screenings for fentanyl and
methamphetamine, were observed, especially
after lockdown. Emergency room visits doubled
after March, when lockdown started. The presence
of fentanyl in urine drug screens doubled after
lockdown and continued to increase in the
remaining months of the year. The overall presence
of fentanyl increased by 28% between January and
December. The presence of methamphetamines in
drug screens remained stable following lockdown
but dramatically increased in the later part of the
3
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year. Overall, the presence of methamphetamines
increased by 200% between January and
December. Drug screen results for marijuana,
nicotine, and cocaine remained relatively stable
during the year without any dramatic changes after
lockdown (Figure 2).
Figure 3 outlines the presence of fentanyl in urine
drug screens during each month of 2020. Overall,
the presence of fentanyl in urine drug screens
showed a positive trend. The highest rate was
33% of individuals screening positive for fentanyl
in November. Across the 12-month period, 20%
of individuals screened positive for fentanyl. The
cumulative amount of fentanyl also increased in
drug screens over the 12-month period.
Figure 4 outlines the presence of methamphetamine
in urine drug screens during each month in 2020.
Overall, the presence of methamphetamines in urine
drug screens showed a positive trend. The highest
rate was 33% of individuals screening positive

34
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32

First Economic
Impactment
Payment

Quarantine

for methamphetamines in December. Across the
12-month period, 20% of individuals screened
positive for methamphetamines. The cumulative
amount of methamphetamine also increased in
drug screens over the 12-month period.

DISCUSSION
This study was a preliminary exploration of drugscreen results and emergency room visits among
a cohort of individuals in recovery for an opioid
use disorder when the social distancing measured
related to COVID-19 went into effect. Among this
sample, 46% of individuals were homeless, and
77% had a PHQ-9 score20 that corresponded with
moderate-severe depression. The psychosocial
stress and severity of opioid use disorder puts this
group of individuals at high risk for an overdoserelated fatality. Because this medication-assisted
treatment program is low barrier, focused on harm
reduction, and targets the most acute patients, the
results should be interpreted with caution.
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Figure 2. Overall Patterns of Drug Screens and Emergency Room Admissions by Month in 2020. Notable
state mandated regulations are indicated with gray lines.
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Figure 3. Presence of Fentanyl in Urine Drug Screens by Month
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Figure 4. Presence of Methamphetamine in Urine Drug Screens by Month
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The following hypotheses may explain, in part,
the rising presence and amounts of fentanyl
and methamphetamines in urine drug screens
following lockdown. First, social support is
integral to recovery and treatment of substance
use disorders.21,22 By playing a protective role in
recovery, peer support groups (ie, group-based
cognitive behavioral therapy and psychotherapy)
promote self-efficacy (ie, one’s perception of control
over their substance use behaviors).23 Increased
self-efficacy also predicts recovery and reduced
substance use.23,24 During the pandemic, public
health agencies needed to limit group sizes and
enact social distancing measures for patient safety.
As a result, many recovery services at the clinic
were quickly transitioned to telehealth or disrupted.
For example, the peer navigator support network,
which assists individuals in recovery with housing
and transportation to appointments, was disrupted.
In addition, using telehealth was a barrier to care for
some individuals, especially in Penobscot County’s
rural areas.25,26
The Maine Center for Disease Control and
Prevention reported that the supply of nonpharmaceutical fentanyl and its analogs peaked
in 2017 and then gradually declined. However,
COVID-19 led to instability in drug supply and
unpredictable patterns of substance use.27 Among
this cohort of individuals, the presence and amount
of fentanyl and methamphetamines in drug screens
increased after lockdown, but the presence and
amounts of nicotine, marijuana, and cocaine did
not change.
Emergency room visits also increased after
lockdown. Although the nature of these visits was
not characterized, this finding may signal the overall
declining health and well-being of this cohort.
Given the substantial risk of overdoserelated fatalities associated with fentanyl and
methamphetamine use, the results of this study
highlight the emergent need for more drastic harmreduction services statewide and nationwide to
protect individuals at risk for drug-related overdoses
and fatalities.
Current and future strategies for harm reduction
Overdose-related deaths are a public health
emergency in Maine, and the state’s Department of
Health and Human Services has mandated several
harm-reduction strategies. These strategies include
https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss1/2
DOI: 10.46804/2641-2225.1099

distributing naloxone at opioid treatment programs
to minimize the risk of death from an overdose
and expanding telehealth to include medicationassisted treatment and counseling. According to
Maine’s Annual Strategic Action Plan report by
the Governor’s Office of Policy Innovation and
the Future, 55,788 doses of naloxone reversed
1136 opioid overdoses in 2020. Other agenda
items include training more recovery coaches and
providing medication-assisted treatment within the
Department of Corrections to expand treatment to
individuals in the state’s prison and jail systems.28
Another important initiative undertaken by the state
is supporting emergency departments to oversee
medication-assisted
treatment.28
Individuals
who have a substance use disorder and use
intravenously are more likely to have hospital
admissions for bacteremia, osteomyelitis, softtissue infections, endocarditis, and cellulitis.29
Individuals with substance use disorders are up to 3
times more likely to be discharged against medical
advice due to undertreated withdrawal syndromes,
symptoms of substance use disorder (eg, cravings),
and hospital staff having stigma associated with
substance use.30 Therefore, more resources
should be allocated in Maine for inpatient addiction
treatment. In Maine, at the time this manuscript
was prepared, 79.94% of the population was fully
vaccinated against COVID-1931. I urge providers to
prioritize administering the vaccine to people who
have a substance use disorder, especially those
who are also homeless.
Limitations
This study is limited by its small sample size. Only
charts that met the inclusion criteria could be
analyzed, although a broad inclusion criterion was
established to capture more data. No protocol was
developed to ensure adherence to buprenorphine
maintenance therapy, and the analysis did
not consider the amounts of buprenorphine
breakdown products present in urine drug screens.
Therefore, individuals who did not strictly adhere
to maintenance therapy with Suboxone were
still included in the results. In addition, this study
explored the prevalence of substance use in
this highly at-risk group of individuals during the
pandemic. In the future, more advanced analysis
focusing on polysubstance use and the associated
risk of overdose-related death would be informative.
Finally, a urine drug screen has limited diagnostic
value and does not accurately measure monthly
substance use. Instead, the screen can only detect
6
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the presence and quantity of a substance at a given
moment in time.

Overall, this cohort is unique. These individuals
face a significant burden of psychosocial stress, as
almost half of them were homeless, all of them are
in recovery for an opioid use disorder, and many of
them have a co-occurring stimulant use disorder.
Conflicts of interest: None
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